{"id":"drug-conversion-to-sirolimus","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Hyperlipidemia"},{"rate":"10-30","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Anemia"},{"rate":"10-15","effect":"Delayed wound healing"},{"rate":"5-15","effect":"Mouth ulcers"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"1-5","effect":"Pneumonitis"}]},"_chembl":{"chemblId":"CHEMBL263427","moleculeType":"Small molecule","molecularWeight":"1189.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sirolimus (rapamycin) binds to FKBP12 and inhibits the mammalian target of rapamycin (mTOR), a key signaling protein in cell proliferation and survival. This mechanism reduces T-cell and B-cell activation, making it effective as an immunosuppressant in transplant recipients. Drug conversion protocols involve switching patients from other immunosuppressants (such as calcineurin inhibitors) to sirolimus-based regimens to optimize long-term graft outcomes and reduce nephrotoxicity.","oneSentence":"Sirolimus is an mTOR inhibitor that suppresses T-cell proliferation and immune activation to prevent organ rejection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:35:37.647Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in renal transplant recipients"},{"name":"Conversion therapy in transplant patients to reduce calcineurin inhibitor exposure"}]},"trialDetails":[{"nctId":"NCT02793544","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide","status":"COMPLETED","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2016-12","conditions":"Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma","enrollment":80},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT03577431","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-29","conditions":"Liver Transplant","enrollment":9},{"nctId":"NCT03413722","phase":"","title":"Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-02-01","conditions":"End Stage Renal Disease","enrollment":30},{"nctId":"NCT00896012","phase":"PHASE4","title":"Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2008-01","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT02939365","phase":"PHASE4","title":"Precision Medicine Offers Belatacept Monotherapy","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2019-02","conditions":"Transplantation","enrollment":""},{"nctId":"NCT01935128","phase":"PHASE4","title":"Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction","status":"COMPLETED","sponsor":"University of Toledo Health Science Campus","startDate":"2013-07-03","conditions":"Renal Transplant","enrollment":55},{"nctId":"NCT02974686","phase":"PHASE4","title":"Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2016-11","conditions":"Kidney Transplant Rejection, Gastrointestinal Disorder, Functional","enrollment":1},{"nctId":"NCT00866879","phase":"PHASE4","title":"Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-06","conditions":"Renal Transplant Rejection","enrollment":275},{"nctId":"NCT01878786","phase":"PHASE2, PHASE3","title":"A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys","status":"TERMINATED","sponsor":"Matthew Cooper","startDate":"2013-06","conditions":"Delayed Graft Function","enrollment":25},{"nctId":"NCT01636466","phase":"PHASE3","title":"The Everolimus-Transplant Exit Strategy Trial (E-TEST)","status":"TERMINATED","sponsor":"Ashtar Chami","startDate":"2013-06","conditions":"Kidney Failure, Chronic","enrollment":1},{"nctId":"NCT01998789","phase":"PHASE2","title":"Everolimus Post Orthotopic Liver Transplant","status":"UNKNOWN","sponsor":"Tomoaki Kato","startDate":"2013-10","conditions":"Orthotopic Liver Transplant","enrollment":50},{"nctId":"NCT01797315","phase":"PHASE4","title":"Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol","status":"TERMINATED","sponsor":"University Hospital of Berlin","startDate":"2007-03","conditions":"Renal Transplant Patients at High-risk for Skin Cancer","enrollment":40},{"nctId":"NCT00834496","phase":"","title":"Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation","status":"WITHDRAWN","sponsor":"Thomas Jefferson University","startDate":"2009-01","conditions":"Side Effects of Calcineurin Inhibitors, Renal Toxicity, Hepatic Fibrosis on Biopsy","enrollment":""},{"nctId":"NCT02671318","phase":"PHASE4","title":"Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence","status":"UNKNOWN","sponsor":"Hospital do Rim e Hipertensão","startDate":"2015-09","conditions":"Cytomegalovirus Infections","enrollment":250},{"nctId":"NCT01678937","phase":"","title":"Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-09","conditions":"Liver Transplant Rejection, Immunosuppression","enrollment":31},{"nctId":"NCT00634920","phase":"PHASE4","title":"Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-03","conditions":"Renal Function","enrollment":204},{"nctId":"NCT01609673","phase":"NA","title":"Study of Everolimus in de Novo Renal Transplant Recipients","status":"TERMINATED","sponsor":"Helady Pinheiro, MD, PhD","startDate":"2013-03","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":294,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rapamune"],"phase":"marketed","status":"active","brandName":"Drug conversion to sirolimus","genericName":"Drug conversion to sirolimus","companyName":"Hospital do Rim e Hipertensão","companyId":"hospital-do-rim-e-hipertens-o","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sirolimus is an mTOR inhibitor that suppresses T-cell proliferation and immune activation to prevent organ rejection. Used for Prevention of organ rejection in renal transplant recipients, Conversion therapy in transplant patients to reduce calcineurin inhibitor exposure.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}